Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06287476
Other study ID # H-23043870
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 15, 2024
Est. completion date March 15, 2025

Study information

Verified date February 2024
Source Rigshospitalet, Denmark
Contact Ronan MG Berg, MD, DMSc
Phone 004535451825
Email ronan@sund.ku.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. The aim of this study is to investigate whether individuals with COPD exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass.


Description:

It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. The aim of this study is to investigate whether individuals with COPD exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass. The study participants include a control group and a group with COPD (GOLD I-III). Participants are undergoing three study days: (1) Measurement of maximal aerobic capacity and lung function test, (2) lung tissue mass and alveolar-capillary permeability is measured at rest and again 2 hours later, immediately after the participant has exercised on a bicycle ergometer and (3) supine cardiac output and pulmonary capillary blood volume will be measured at rest and immediately after exercise.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date March 15, 2025
Est. primary completion date March 15, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 80 Years
Eligibility Inclusion criteria - individuals with COPD - Men and women - 45-80 years old - COPD (GOLD stage I to III) - Resting arterial oxygenation > 90% Inclusion criteria - healthy controls - Men and women - 45-80 years old - Non-smokers - Normal lung function - Same sex, age (± 3 years) as the COPD group Exclusion criteria - individuals with COPD - Symptoms of ischemic heart disease - Known heart failure - Symptoms of illness, including fever, within 2 weeks prior to the study - Pregnancy - • Known renal or liver diseaseActive smoking (within 3 weeks) Exclusion criteria - healthy controls - Known chronic lung disease - Symptoms of ischemic heart disease - Known heart failure - Symptoms of illness, including fever, within 2 weeks prior to the study - Pregnancy - Known renal or liver disease - Active smoking (within 3 weeks)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Acute exercise bout on visit 2 and 3
1) a 5-minute warm-up, 2) 4 minutes at 60% of the maximal workload (determined on Study Day 1), 3) 2 minutes active break at 15 watt, 4) 4 minutes at maximal workload.

Locations

Country Name City State
Denmark Center For Physical Activity Research, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Lung tissue mass at rest in COPD vs. controls Lung tissue mass measured at rest by low-dose CT-scan Measured at study day 2
Other Lung tissue mass after exercise in COPD vs. controls Lung tissue mass measured at exercise by low-dose CT-scan Measured at study day 2
Other Rest-to-exercise pulmonary DTPA clearance and lung tissue mass change according to GOLD The physiological change from rest to exercise in lung tissue mass measured by low-dose CT-scan and the physiological change from rest to exercise in DTPA clearance according to different GOLD stages Measured at study day 2
Other Supine pulmonary capillary blood volume after exercise in COPD vs. controls Pulmonary capillary blood volume (VC) after exercise obtained by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Other Supine cardiac output after exercise in COPD vs. controls Cardiac output measured after exercise by a Finometer device Measured at study day 3
Other Supine pulmonary capillary blood volume at rest in COPD vs. controls VC at rest obtained by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Other Supine cardiac output at rest in COPD vs. controls Cardiac output measured at rest by a Finometer device Measured at study day 3
Other Supine pulmonary diffusing capacity to nitric oxide (DLNO) after exercise in COPD vs. controls DLNO measured after exercise by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Other Supine haemoglobin-corrected pulmonary diffusing capacity to carbon monoxide (DLCOc) after exercise in COPD vs. controls DLCOc measured after exercise by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Other Supine alveolar-capillary membrane diffusing capacity (DM) after exercise in COPD vs. controls Membrane diffusion capacity (DM) after exercise obtained by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Other Supine pulmonary diffusing capacity to nitric oxide (DLNO) at rest in COPD vs. controls DLNO measured at rest by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Other Supine haemoglobin-corrected pulmonary diffusing capacity to carbon monoxide (DLCOc) at rest in COPD vs. controls DLCOc measured at rest by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Other Supine alveolar-capillary membrane diffusing capacity (DM) at rest in COPD vs. controls DM after exercise obtained by combined DLCO/NO technique with 5-sec breath-hold Measured at study day 3
Primary Rest-to-exercise pulmonary DTPA clearance change after exercise in COPD vs. controls The physiological change from rest to exercise in DTPA clearance Measured at study day 2
Secondary Pulmonary DTPA clearance at rest in COPD vs. controls Pulmonary DTPA clearance measured by pulmonary DTPA clearance at rest Measured at study day 2
Secondary Pulmonary DTPA clearance after exercise in COPD vs. controls Pulmonary DTPA clearance measured by pulmonary DTPA clearance after exercise Measured at study day 2
Secondary Rest-to-exercise change in lung tissue mass in COPD vs. controls The physiological change from rest to exercise in lung tissue mass measured by low-dose CT-scan Measured at study day 2
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy